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Abstract
Background and aim: Migraine is the most common neurological disorder, affecting approximately 12 % of the
adult population worldwide, caused by both environmental and genetic factors. Three causative genes have been
identified in familial hemiplegic migraine (FHM) families: CACNA1A, ATP1A2, and SCNA1A. Recently, several mutations
in KCNK18 have also been found as causative factors in migraine development. The aim of our study was to identify
the genetic background of migraine in the Polish population.
Material and methods: Sixty patients with migraine without aura (MO) or with different types of migraine with
aura (MA), including sporadic hemiplegic, familial hemiplegic, and probable familial hemiplegic, were screened for
mutations in the four genes previously linked with different types of migraine (ATP1A2, CACNA1A, SCN1A, and KCNK18).
Results: Two missense mutations were found. One novel mutation in SCN1A, encoding α subunit of sodium channel,
causing amino acid change M1500V localized to a region encoding inactivation loop between transmembrane domains III
and IV of the channel, was detected in a female FHM patient. The M1500V mutation was absent in a group of 62 controls,
as well as in the ExAC database. The second, already known missense mutation S231P in KCNK18 was found in a female
MA patient. Additionally, a novel intronic polymorphism possibly affecting alternative splicing of SCN1A, at chr2:16685249,
g.77659T>C, and c.4581+32A>G, located between exons 24 and 25, in a region encoding the inactivation loop of the
sodium channel was found in a female MO patient. No mutations in ATP1A2 or CACNA1A were found in the study group.
Conclusions: The presence of SCN1A mutations and absence of mutations in ATP1A2 or CACNA1A suggest that the
Polish patients represent FHM type 3. On the other hand, the presence of KCNK18 mutation indicated another FHM
subtype. It could be speculated that contrary to other European populations, the genetic basis of migraine in the Polish
population involves mutations in genes not included in the study. Next-generation sequencing methods should be
implemented to identify other migraine-associated variants.
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Introduction
Migraine is the most common neurological disorder, af-
fecting approximately 12 % of the adult population
worldwide, caused by both environmental and genetic
factors. Its heritability is estimated at ca. 40–70 %. Nu-
merous linkage studies and candidate-gene studies have
identified causative genes in migraine without aura (MO)
and migraine with aura (MA). Three such genes have been
identified in familial hemiplegic migraine (FHM). The first
FHM type (FHM1; MIM141500) is related to locus 19p13
and caused by mutations in CACNA1A, encoding alpha
1A subunit of voltage-dependent calcium channel type P/
Q (MIM601011) [1]. Mutations in CACNA1A contribute
also to episodic ataxia (EA2; MIM108500) [2] and spino-
cerebellar ataxia type 6 (SCA6; MIM183086) [3]. The
second FHM type (FHM2; MIM602481) is caused by mu-
tations in ATP1A2 encoding alpha 2 subunit of Na+/K+−
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ATPase (MIM182340) [4]. Finally, the third FHM locus
(FHM3; MIM609634) is at 2q24, and the implicated gene
SCNA1A (MIM182389) encodes α subunit of the neuronal
voltage-gated Na+ channel [5]. Mutations in SCN1A were
also recognized as a cause of epilepsy [6]. Recently,
KCNK18 at locus 10q25.3, encoding K+ channel subfamily
K member 18, has been found to be connected with FHM
classified as other than types 1, 2, and 3 (MIM613655) [7].
Other studies have provided evidence on the influence of
the genetic variants of SLC6A4 encoding a serotonin
transporter on a migraine occurrence [8]. Moreover, re-
cent genome-wide association studies (GWAS) have iden-
tified four novel genetic variants associated with migraine
[9]: rs1835740 modulating glutamate homeostasis and
specific for migraine with aura; rs11172113 implicating
lipoprotein receptor LRP1, which may interact with neur-
onal glutamate receptors; rs10166942 in close proximity to
TRPM8, encoding a cold and pain sensor; and rs2651899 in
PRDM16, with an unclear role [9]. All these variants only
confer a small to moderate risk for migraine, which con-
curs with migraine being a heterogeneous disorder [9]. A
list of single nucleotide polymorphisms in 10 genes was
reported in a large German case-control cohort study of
migraine with aura [10], and recently, several genetic vari-
ants in APOA1BP, TBC1D7, FUT9, STAT6, ATP5B,
AJAP1, TSPAN2, FHL5, C7orf10, and MMP16 have been
found in GWAS performed in Western Europe [11].
To identify the genetic background of migraine in Polish
patients, we screened ATP1A2, CACNA1A, SCN1A, and
KCNK18 for mutations in a group of 60 patients with
migraine without aura or with different types of aura mi-
graine: typical, sporadic hemiplegic and familial hemiple-
gic or probable familial hemiplegic. All patients were
Caucasians of Polish origin.
Materials and methods
Ethics statement
Written consent was obtained from probands, diagnosed
family members, and probands’ relatives according to
the Declaration of Helsinki [12]. The genetic study was
approved by the Ethics Committee of the Medical Uni-
versity of Warsaw (Warsaw, Poland) in compliance with
the national legislation and the Code of Ethical Princi-
ples for Medical Research Involving Human Subjects of
the World Medical Association.
Patients’ clinical description
Sixty patients (47 women and 13 men), mean age 48 ±
13 years, of the Headache Outpatient Clinic and Neuro-
logical Department, with different types of migraine
diagnosed according to the International Headache Soci-
ety (IHS) criteria, 3rd edition [13], were analyzed. The
study group consisted of several subgroups: 4 families
(Table 1—4a, b, c; 7a, b, c; 43a, b, c, d; 47a, b, c) with
familial hemiplegic migraine (FHM3 families) and spor-
adic hemiplegic migraine (SHM1 family), 6 patients with
probable familial hemiplegic migraine (F?HM—families of
patients with hemiplegic migraine not seen), 7 patients
with sporadic hemiplegic migraine (SHM), 11 patients
with MA, and 23 patients with MO. Two members from
FHM family no. 7 were also diagnosed with epilepsy with
grand mal attacks (father and older son). One patient di-
agnosed SHM also had mental retardation. One patient
with MO also had episodic ataxia (EA). Family no. 43 was
examined for the presence of mutations in Leiden factor
V. This analysis revealed the presence of the variant
G1691A, c.1746G>A p.Arg534Gln, rs6025 in this family
and in one family member (mother) was possibly associ-
ated with ischemic stroke. The study was performed at the
Institute of Hematology and Blood Transfusion in
Warsaw, according to standard protocols based on Sanger
sequencing. Only the family 43 was examined for Leiden
factor V genetic variants, and these tests were part of rou-
tine diagnostic practice at the Institute of Hematology and
Blood Transfusion in Warsaw and were made available
under standard medical care. The migraine patients were
interviewed and examined in the Headache Outpatient
Clinic or at the Department of Neurology of Warsaw
Medical University. The diagnosis was performed by an
experienced neurologist. Duration of the disease ranged
between 1 and 40 years (mean duration 21 + 11 years),
and the frequency of migraine attacks ranged between
1 attack/1 week to 1 attack/12 months. Patient profile
is presented in Table 1. As a control group, we used
our existing database of 62 samples of whole-exome
sequencing, which were screened for the presence of
identified variants.
Sanger sequencing
Genomic DNA was extracted from peripheral blood leu-
kocytes using standard salting-out method. Exons 4, 5, 13,
16, 17, 24, 26, 29, 32, and 36 of CACNA1A, exons 6, 14,
15, 16, 18, 20, 23, 24, and 26 of SCNA1A, exons 9, 16, 17,
18, 19, and 22 of ATP1A2, and exons 1, 2, and 3 of
KCN1K18 (all with flanking intronic sequences) were se-
quenced using automated, fluorescent sequencing
method. Genes and the exons were chosen on the basis of
the frequencies of known migraine-causing mutations
(Leiden Familial Hemiplegic Migraine Variation Database).
In brief, the amplicons were amplified with Master Mix
Kit and Hot Start Master Mix Kit (Qiagen) using genomic
DNA from each patient. Primers were designed using Pri-
mer Premier software (Additional file 1). The annealing
temperature of 58 °C was applied for all primers. Exon 26
of SCN1A and exon 3 of KCNK18 were amplified in over-
lapping fragments. Resulting amplicons were purified with
Exonuclease I/FastAP (Fermentas) and sequenced using
ABI PRISM 3130 Genetic Analyzer (Applied Biosystems)
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Among the 60 Polish patients studied, we found a single
nucleotide polymorphism c.4498A>G, rs376885324, in
exon 24 of SCN1A leading to amino acid substitution
M1500V (Fig. 1a). This variant was found in a female
FHM patient and had not been linked to an FHM clin-
ical phenotype before (see Table 2). The family history of
the patient suggested autosomal dominant inheritance pat-
tern, and according to clinical interview, seven members of
Table 1 Clinical phenotypes and polymorphisms in migraine-




Sex Clinical phenotype SCN1A, CACNA1A, ATP1A2, KCNK18
1 1980 M MA
2 1976 F F?HM c.4498A>G, p.M1500V,
rs376885324 (ex. 24 SCN1A)
3 1978 F MA rs2298771 (ex. 16 SCN1A)
4a 1952 F FHM rs17846715 (ex. 16 ATP1A2)
4b 1978 F FHM
4c 1980 F FHM
5 1967 F MO
6 1967 F MO
7a 1954 M FHM+ EPI
7b 1982 M FHM+ EPI rs2298771 (ex. 16 SCN1A),
rs16012 (ex. 13 CACNA1A)
7c 1984 M MO rs2298771 (ex. 16 SCN1A)
8 1980 M SHM
9 1958 F F?HM
10 1944 F MO Novel intronic polymorphism
c.4581 + 32A>G, between
ex. 24 and 25
11 1946 F MO
12 1954 F MO
13 1982 F MA
14 1966 F MO rs2298771 (ex. 16 SCN1A)
15 1962 M MO
16 1972 F MA c.691T>C, p.S231P, rs363315
(ex. 3 KCNK18), rs16016
(ex. 16 CACNA1A)
17 1962 M MO
18 1968 F MO
19 1943 F MO rs2298771 (ex. 16 SCN1A)
20 1963 F F?HM rs41288127, rs55884181
(ex. 22 ATP1A2)
21 1957 F F?HM
22 1978 F MO rs2298771 (ex. 16 SCN1A)
23 1968 F MA rs2298771 (ex. 16 SCN1A)
24 1934 F MO rs2298771 (ex. 16 SCN1A)
25 1960 F MO
26 1953 F MA rs16012 (ex. 13 CACNA1A)
27 1973 F SHM rs41276894 (ex. 4 CACNA1A)
28 1977 F F?HM
29 1988 M SHM+MR
30 1969 F F?HM rs61734524 (ex. 9 ATP1A2)
31 1973 F SHM rs17846715 (ex. 16 ATP1A2)
32 1976 M MO rs2298771 (ex. 16 SCN1A)
33 1987 F SHM rs17846715 (ex. 16 ATP1A2),
rs41288127 (ex. 22 ATP1A2)
Table 1 Clinical phenotypes and polymorphisms in migraine-
related genes (SCN1A, CACNA1A, ATP1A2, KCNK18) in the study
group (Continued)
34 1970 F MO rs2298771 (ex. 16 SCN1A)
35 1972 F MO
36 1968 F MO
37 1966 F MA rs2298771 (ex. 16 SCN1A)
38 1969 F MA
39a 1988 F MO
39b 1960 F MO
40 1970 F MO
41 1974 F MO
42 1958 F MO
43a 1989 M MO (mutation in
Leiden factor V)
rs61734524 (ex.9 ATP1A2),
rs16016 (ex. 16 CACNA1A)
43b 1994 F FHM (mutation in
factor V Leiden)
rs61734524 (ex.9 ATP1A2)
43c 1970 F FHM (mutation in
factor V Leiden)
rs61734524 (ex.9 ATP1A2),
rs16016 (ex. 16 CACNA1A)




44 1958 F MO + EA
45 1960 F MA
46a 1943 F SHM mother rs61734524 (ex. 9 ATP1A2)
46b 1984 M SHM Not tested
46c 1943 M SHM father
47 1962 F MA rs17846715 (ex. 16 ATP1A2)
48 1967 M SHM
49 1963 F MA
50 1972 F SHM rs61734524 (ex. 9 ATP1A2),
rs17846715 (ex. 16 ATP1A2)
51 1959 F MA rs2298771 (ex. 16 SCN1A)
Description of clinical phenotype: EA, episodic ataxia, Epi epileptic seizures,
F?HM probable familial hemiplegic migraine, FHM familial hemiplegic migraine,
MA migraine with typical aura, MO migraine without aura, MR mental retardation,
SHM sporadic hemiplegic migraine
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the proband’s family were also affected by migraine, includ-
ing a sister, the father, two father’s brothers, a cousin, and
the grandmother (Fig. 2). Unfortunately, the material for
genetic testing from other family members was unavailable,
but the patient’s sister and father were examined clinically
and diagnosed with FHM in our clinic.
Bioinformatic assessment using PolyPhen-2 HumDiv
[14] showed that the M1500V variant is probably dam-
aging with a score of 0.982 (sensitivity, 0.75; specificity,
0.96). According to the Protein Variation Effect Analyzer
(PROVEAN) and Sorting Intolerant From Tolerant (SIFT)
tools [15, 16], the variant is damaging (score −3.68) and
deleterious (score 0.001). The MutationTaster prediction
tool [17] also describes the variant as disease-causing.
M1500V was not detected in our 62 controls or in the
ExAC database, which contains data for the genomic re-
gion of interest from 60,000 DNA samples, including
more than 30,000 samples from European populations.
However, the mutation is present in the Ensembl database
with a frequency of 1:8593.
Fig. 1 Mutations in migraine-causing genes. a Single nucleotide substitution at c.4498 A>G, resulting in novel amino acid change M1500V,
was found in SCN1A in a patient with FHM (rs121918632, NG_011906.1, Gene ID: 6323). b A novel intronic polymorphism at chr2:16685249,
g.77659T>C, c.4581 + 32A>G, located between exons 24 and 25, predicted to affect alternative splicing of SCN1A, in a gene region encoding
inactivation loop of sodium channel was found in a patient with MO. c Mutation at c.691T>C, resulting in amino acid change S231P, in KCNK18
(rs363315, NG_028085.1, Gene ID 338567) was found in a patient with MA
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In addition to the M1500V mutation, we identified sev-
eral synonymous single nucleotide polymorphisms in
SCN1A in the study group and one missense variant at
chr2:166892788, g.37362G>A, c.3199G>A, rs2298771,
which the frequency of occurrence, according to data
from the dbSNP database, is 24 %, and in our study group
was 20 % (in 12 patients with different phenotypes), result-
ing in amino acid change A1067T (Table 1, Fig. 3).
According to PROVEAN and SIFT, this amino acid substi-
tution is neutral with a score of −0.068, and according to
PolyPhen-2 mutation, is benign with a score of 0.000. The
MutationTaster scored the variant as a neutral poly-
morphism that might change protein feature. This variant
has been assigned to myoclonic astatic epilepsy phenotype
[18], which is in accordance with our study showing its
presence in one family (no. 7; three patients, 5 % of the
study group) with epilepsy and FHM.
In a female patient with migraine without aura and
with onset at puberty, we found a novel intronic poly-
morphism possibly affecting alternative splicing of
SCN1A, at 2:166852491, g.77659T>C, c.4581+32A>G, lo-
cated between exons 24 and 25, in a region encoding
inactivation loop of the channel (Fig. 1b). The patient had
migraine with a typical course: high-intensity attacks last-
ing for a few hours with frequency 1 per month. The
patient’s familial history is surprising. Her two sisters were
diagnosed with a probable CADASIL (cerebral autosomal
dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy), but with no mutation in NOTCH3.
One of the sisters suffered from dementia and was diag-
nosed with disseminated and diffuse changes in brain
MRI interpreted as the beginning of demyelination (she
died at the age of 60 years, and no medical records were
available). The patient’s mother died at the age of 69, likely
from a stroke. The patient’s father and brother and the pa-
tient’s siblings’ children are healthy. The variant could not
be evaluated by the PROVEAN, SIFT, or Poly-Phen2 tools
due to a lack of data. This variant is absent in the ExAC
database, but insertion A/AT has been found at this nu-
cleotide position (http://exac.broadinstitute.org/region/2-
166852491-166852491), with a frequency of ca. 0.000008.
The substitution reported here could be a novel rare
intronic variant. According to the MutationTaster, the
variant could alter various protein features, including do-
mains and motifs, downstream of the altered splice site,
as presented in Table 3.
CACNA1A and ATP1A2
We found several synonymous single nucleotide poly-
morphisms in the CACNA1A and ATP1A2 genes, as
summarized in a Table 1.
Table 2 Clinical phenotype of FHM patient with mutation
M1500V in exon 24 of SCN1A
Hemiplegic migraine (HM) onset (years) 22
Triggering factors of HM Emotional stress
Hemiplegia during aura phase +
Sensory disturbances during aura phase +
Visual disturbances during aura phase +
Aphasia during aura phase +
Aura duration (min) 60
Headache duration (h) 4–24





Other types of headache MO, MA
Fig. 2 Pedigree of FHM patient with M1500V mutation in exon 24 of SCN1A
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Fig. 3 A1067T mutation in SCN1A. Exon 16 with flanking intronic regions of SCN1A gene was analyzed as described in the “Materials and
methods” section. The missense variant at chr2:166892788, g.37362G>A, c.3199G>A, rs2298771 resulting in amino acid change A1067T
found in 12 patients with different phenotypes (20 % of the study group) and present at the high frequency of 24 % in dbSNP database
is indicated by frame
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KCNK18
We identified a known mutation at c.691T>C, rs363315,
in exon 3 of KCNK18 gene leading to amino acid substi-
tution S231P in a female patient diagnosed with mi-
graine with aura (Fig. 1c).
Additionally, in our study group, one family (no. 43; four
patients, 6.6 % of the study group) had mutation in Leiden
factor V, associated with blood clots. In this family, we did
not find any mutations in SCNA1A, CACN1A, KCNK18,
and ATP1A2 reported before as migraine-causing.
Discussion
Migraine is the most common neurological disorder
with a well-defined genetic background, but until now,
no migraine-causing mutations have been studied in
Polish patients [19, 20]. For genetic screenings in this
study, we have selected exons 4, 5, 13, 16, 17, 24, 26, 29,
32, and 36 of CACNA1A; exons 6, 14, 15, 16, 17, 23, 24,
and 26 of SCNA1A; exons 9, 16, 17, 18, 19, and 22 of
ATP1A2; and exons 1, 2, and 3 of KCN1K18 (all with
flanking intronic sequences). We have selected these
genetic regions according to the frequencies of found
disease-causing genetic variants stated in Leiden Familial
Hemiplegic Migraine Variation Database and to the
highest probability of genetic variant occurrence.
Overall, our study sheds the first light on the gen-
etic background of migraine in the group of Polish
patients, and we believe that this study will help us
to stratify our pool of patients in terms of their gen-
etic status of the most common variants of the four
genes associated with migraine for future large-scale
genetic studies.
We have identified a novel FHM-linked M1500V mu-
tation in SCN1A, putatively affecting the inactivation
loop of the sodium channel protein and confirming pre-
vious reports found the S231P mutation in KCNK18 in a
patient with migraine with aura. Surprisingly, no
disease-causing variants in ATP1A2 and CACNA1A were
found in the study group.
The novel mutation M1500V substitutes evolutionarily
highly conserved methionine residue in sodium channel
protein type 1 subunit alpha (P35498). The functionally
important amphipathic methionine involved in playing
binding/recognition of hydrophobic ligand methionine is
substituted with hydrophobic valine with a largely non-
reactive aliphatic side chains and packed in the protein
interior. There is no direct data indicating that M1500V
is causally linked to the disease, but it localizes next to
the known F1499L mutation (dbSNP:rs121918632), in-
volved in episodes of elicited repetitive daily blindness
(ERDB) co-segregating with familial hemiplegic mi-
graines [21] and with I1498M [22]. The Met > Val substi-
tution is in the IFM motif responsible for fast channel
inactivation, located in the inactivation intracellular gate
between domains III and IV, each composed of six trans-
membrane segments called S1–S6 (Fig. 4). Since normal
fast inactivation of the channel results from occlusion of
the intracellular part of the channel by a short loop be-
tween domains III and IV, mutation in this region could
disturb the inactivation. For example, in oocyte expression
studies, R1648H accelerated recovery from inactivation,
W1204R shifted the voltage-dependence of activation and
inactivation in the negative direction, R859C shifted the
voltage-dependence of activation in the positive direc-
tion, and T875M enhanced slow inactivation [23]. The
alterations due to R1648H and W1204R are predicted
to increase sodium channel activity and neuronal excit-
ability, whereas those due to R859C and T875M should
decrease the channel activity and neuronal excitability
[23]. Further, in vitro studies are necessary to assess the
impact of the M1500V mutation on sodium channel
inactivation.
The second mutation we found is S231P in KCNK18.
This mutation has already been well characterized and
shown to be migraine-related but not to influence the
activity of the TRESK K2P potassium channel encoded
by KSNK18 [24]. Other studies on this variant also
showed relationship to migraine with typical aura [25].
Table 3 Predicted loss of protein features downstream of the splice site altered by c.4581+32A>G variant in SCN1A
Start (aa) End (aa) Feature Details
1523 1821 Repeat IV
1537 1537 Conflict F ->L (in [7]; CAA46439/M91803).
1537 1560 Transmem Helical; name = S1 of repeat IV; (by similarity).
1572 1595 Transmem Helical; name = S2 of repeat IV; (by similarity).
1602 1625 Transmem Helical; name = S3 of repeat IV; (by similarity).
1636 1657 Transmem Helical; voltage sensor; name = S4 of repeat IV; (by similarity).
1673 1695 Transmem Helical; name = S5 of repeat IV; (by similarity).
1762 1786 Transmem Helical; name = S6 of repeat IV; (by similarity).
1788 1788 Carbohyd N-linked (GlcNAc…) (potential).
1915 1944 Domain IQ
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Accordingly, we found the KCNK18 mutation in a pa-
tient with migraine without aura.
The novel intronic polymorphism identified in a family
with a CADASIL-like phenotype and migraine could
affect the splicing of SCN1A transcript. According to the
MutationTaster, this variant may influence splicing (e.g.,
increase or gain of splice donor site at position g.77658)
and affect protein features (for details, see Table 3).
Voltage-dependent inactivation of Na+ channels is a
consequence of voltage-dependent activation, and an inac-
tivated Na+ channel enters a non-conducting and non-
transmitting signals state, as the inactivation gate, the
cytoplasmic loop linking domains III and IV of the α sub-
unit, obstructs the open pore [26]. Due to its the location
in the exon 24, encoding the inactivation loop, the variant
seems likely to produce a constitutively inactive form of
sodium channel alpha subunit leading to the permanent
shut down of synaptic transmission. Detailed functional
studies are needed to elucidate the link between gener-
ation of various alternative splicing forms and biological
pathomechanisms and clinical phenotype of migraine.
Additionally, based on our studies, it could be specu-
lated that the factor Leiden V mutation found in one
family carrying no causative mutations in SCNA1A,
CACN1A, KCNK18, or ATP1A2 is a sole cause of mi-
graine with aura and vision disability and strokes in that
family, in line with several reports showing a linkage
between migraine and Leiden factor variants [27, 28].
Future perspectives
We suggest that mutations located in other parts of the
analyzed genes or in other genes, not yet shown to be con-
nected with migraine, cause various clinical forms of the
disease in the Polish population. We postulate that next-
generation sequencing (NGS) methods, e.g., whole-exome
sequencing or whole-genome sequencing, should be
used to identify comprehensively migraine-causative
mutations. This is reinforced by the fact that recent
large-scale studies from European populations have
provided an extensive list of susceptibility genes linked
to migraine. The list of candidate genes linked with
FHM occurrence includes: APOA1BP, TBC1D7, FUT9,
STAT6, ATP5B, AJAP1, TSPAN2, FHL5, C7orf10, and
MMP16 [11].
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Fig. 4 Transmembrane organization of sodium channel α subunit. The alpha subunit of the channel comprises four repeat domains (I–IV), each
containing six membrane-spanning segments (1–6). The highly conserved segment 4 acts as the voltage sensor of the channel close to the pore
for ion entry. After Na+ has entered the cell and the membrane’s potential reached its maximum, the channel inactivate by closing the inactivation
loop. Mutation M1500V could abolish channel inactivation and lead to its constitutive activity and firing of the synapses; however, further functional
studies are needed to verify this assumption. Adapted from Brackenbury and Isom [29]
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